Skip to content
Search

Latest Stories

Follow Us:
Top Stories

Dark magic: Drug companies and the art of deception

Dark magic: Drug companies and the art of deception
Getty Images

Pearl is a clinical professor of plastic surgery at the Stanford University School of Medicine and is on the faculty of the Stanford Graduate School of Business. He is a former CEO of The Permanente Medical Group.

Magicians know the key to a convincing trick is misdirection.


They instruct you to follow the left hand so that you’ll ignore the right, which is subtly palming a ball or pulling an ace from the sleeve. The art of the illusion hinges on the magician’s ability to divert attention from where the real action is happening. And, therefore, every illusion conceals the truth.

Similarly, the U.S. biopharmaceutical industry has relied on subtle forms of misdirection in response to increased scrutiny from Congress, the Biden administration and health policy experts.

Here are three illusions drug companies have crafted to maintain massive profitability:

Illusion No. 1: A Death-Defying Feat

Drug research and development (R&D) has, for decades, gifted humanity with medical wonders: antibiotics, statins, cancer therapies and HIV/AIDS treatments.

In the 21st century, however, drug innovation has slowed while pharma companies have made exorbitant pricing a key business strategy. Over the past 18 years, biopharma companies have earned an average gross profit margin of 77%. Last year, the five largest pharma firms generated more than $81.9 billion in profits.

To combat runaway drug prices, Congress passed the Inflation Reduction Act last year, allowing the U.S. government to negotiate prices for a limited number of expensive medications starting in 2026.

The pharmaceutical sector immediately filed lawsuits. In public remarks, drug spokespeople have created the illusion that any reduction in drug-industry profits will destroy R&D innovation and harm millions of patients.

The Hidden Truth

Hidden in this illusion are three facts drug companies don’t want Americans to know. Combined, these truths tell a different story about pharmaceutical research and development.

First, an overwhelming percentage of drug prices gets channeled into corporate profits and administrative costs, not R&D. In fact, a report during the height of the pandemic found that 7 in 10 major drug companies spent more on marketing and sales than R&D.

Second, research concludes that price constraints would minimally impact drug discovery. The Congressional Budget Office estimates that reducing the pharmaceutical revenues would result in just one less drug over the next decade and a total of 1% fewer medications over the next 30 years.

The third and most pernicious part of the illusion is getting people to ignore how many Americans are harmed by the unaffordability of life-essential medications. One example is insulin prices, which have tripled over the past decade. As a result, researchers from Yale found 25% of children with type 1 diabetes are given lower doses by their parents than their physicians recommend.

Nearly 1 in 4 Americans on prescription drugs now report difficulty affording their medications. That is the hidden truth. Exorbitant Rx prices hurt and kill far more Americans than the supposed loss of R&D ever would.

Illusion No. 2: The Statue Of Liberty Trick

Once Americans buy into the illusion that exorbitant drug prices are necessary to save lives, pharmaceutical companies move on to the next sleight of hand.

It goes like this: The United States, alone, must shoulder the enormous burden of drug prices.

Right now, Americans pay 2.4 to 3.4 times more for medications than in peer nations.

Much of the disparity in spending dates back to 2003 when Congress passed a law prohibiting the U.S. government from negotiating drug prices. And without any pricing regulations in place, domestic drug companies have pushed the boundaries ever higher. Over the past two years, nearly half of FDA approved medications have debuted above $150,000 with several topping $1 million per patient.

Outside of the United States, excessively high drug prices are a rarity.

Ozempic exemplifies the problem. This diabetes drug helps people lose significant weight while also avoiding heart attacks. A month’s supply of it costs $936 in the United States. In Japan, it sells for $169. It’s just $93 in the UK, $87 in Australia and $83 France.

Each of these countries has instituted drug-pricing controls and caps on drugmaker profits. If our nation adopted the same regulations, we could prescribe Ozempic to every overweight and obese American, and affordably solve the obesity epidemic. But under current retail pricing, doing so would increase drug spending $1.5 trillion per year, raising overall healthcare costs by 25%.

The Hidden Truth

The illusion here is that drug prices in other wealthy nations are non-negotiable.

But of course, that’s not accurate. American drug companies could play hardball with peer countries, refusing to sell their medications unless a more equitable pricing structure can be reached.

But why bother when you can simply stick Americans with the bill?

Illusion No. 3: What’s In Your Pocket?

When it comes to purchasing prescription drugs, there are two prices. There’s the very high retail price drug companies charge and the much-smaller amount insured patients pay when they pick up their medications (the out-of-pocket expense).

Since out-of-pockets are only small fraction of the total drug expense, drug companies would like Americans to concentrate on those dollars. But that requires people to assume the rest of the money—paid by the government or private businesses—is free.

The Hidden Truth

The reality is that workers and taxpayers wind up paying the price for expensive medications in two ways:

1. Workers earn less pay as benefit costs increase. That’s because employers treat wages and healthcare benefits as a single expense. As medical costs soar, raises disappear and salaries stagnate.

2. Taxpayers either pay more or get less. When medical costs rise, the government must either raise taxes or cut programs, including school funding and public safety.

Deception and misdirection can be sources of wonder at magic shows. But illusions in healthcare prove to be disturbing, dangerous and deadly.


Read More

Virginia Gov. Abigail Spanberger delivers the Democratic response to U.S. President Donald Trump's State of the Union address on February 24, 2026 in Williamsburg, Virginia.

Virginia Gov. Abigail Spanberger delivers the Democratic response to U.S. President Donald Trump's State of the Union address on February 24, 2026 in Williamsburg, Virginia.

Getty Images, Mike Kropf

Three Questions Linger After State of the Union Speech

Anyone tuning into the State of the Union expecting responsible governance was sorely disappointed. What they got instead was pure Trumpian spectacle.

All the familiar elements were there: extended applause lines, culture-war provocation, even self-congratulation, praising the U.S. hockey team and folding its victory into a broader narrative of national resurgence. The whole thing was show business, crafted for reaction rather than reflection, for clips rather than consensus.

Keep ReadingShow less
Two individuals Skiing in the Milano Cortina 2026 Winter Paralympic Games.

Oksana Masters of Team United States celebrates after winning gold in the Para Cross Country Skiing Sprint Sitting Final on day four of the Milano Cortina 2026 Winter Paralympic Games at Tesero Cross-Country Skiing Stadium on March 10, 2026 in Val di Fiemme, Italy.

Getty Images, Buda Mendes

The Paralympics Challenge Everything We Think We Know About Sports

If you’re a sports fan, you likely watched coverage of the 2026 Winter Olympics in Milano Cortina. But will you watch the Paralympics when approximately 665 athletes are expected in Italy to compete in the Para sports of alpine skiing, biathlon, cross-country skiing, ice hockey, snowboarding, and wheelchair curling?

The Paralympics, so-called because they are “parallel” to the Olympics, stand alone as the globe’s premier sporting event for elite athletes with disabilities. According to the International Paralympic Committee, 4,400 disabled athletes competed in the 2024 Paris Summer Games in track and field, swimming, and twenty other sports.

Keep ReadingShow less
U.S. Capitol.

Could Trump declare a national emergency to control voting in the 2026 midterms? An analysis of emergency powers, election law, and Congress’s role in protecting democracy.

Photo by Andy Feliciotti on Unsplash

To Save Democracy, Congress Must Curtail the President’s Emergency Powers

On February 26, the Washington Post reported that allies of President Trump are urging him to declare a national emergency so that he can issue rules and regulations concerning voting in the 2026 election. The alleged emergency arises from the threat of foreign interference in our electoral process.

That threat is based on now fully debunked reports that China manipulated registration and voting in 2020. The National Intelligence Council explained that there were “no indications that any foreign actor attempted to alter any technical aspect of the voting process in the 2020 US elections, including voter registration, casting ballots, vote tabulation, or reporting results.”

Keep ReadingShow less
Elite Insulation and the Fragility of Equal Access

A protest group called "Hot Mess" hold up signs of Jeffrey Epstein in front of the Federal courthouse on July 8, 2019 in New York City.

(Photo by Stephanie Keith/Getty Images)

Elite Insulation and the Fragility of Equal Access

In America: What We Want, What We Have, What We Need, I argued that despite partisan division, Americans share core expectations. They want upward mobility that feels real. They want elections that are credible. They want markets where new entrants can compete. They want rules that bind concentrated wealth. They want stability without stagnation.

The Epstein case directly tests those expectations.

Keep ReadingShow less